IL17A and lung carcinoma: Contrasting anti and protumor effects have also been reported within the same tumor type as seen in melanoma (70, 71) and lung cancer (72, 73) suggesting that TME heterogeneity independent of tissue of origin may also play a contributing role in IL-17 response.